EGF with GHRP-6

The receipt

Tested together in people

2 randomized trials, Phase I/II and Phase III (2024, 2026)

Evidence on the combination

Evidence · Controlled trials

Hernández-Bernal et al., 2024 · Hernández-Bernal et al., 2026

What each does alone

• Skin & Hair · CreamEGFGrowth factor in face serums and Cuba’s ulcer drug Heberprot-P. Its double-blind acne trial: 20 people.Evidence · Controlled trialsGray marketChecked Oct 11
• Muscle & Growth Hormone · Daily shotGHRP-6The 1984 original, now taken mostly for its hunger kick. Its human data: single-dose growth-hormone tests.Evidence · Human pilotsGray marketChecked Oct 11

Mechanism overlap · reasoning, not evidence

EGF

Protein — Human Growth Factor

GHRP-6

Peptide — Growth Hormone Secretagogue (Ghrelin Receptor Agonist)

Reasoning, not evidence: what each is described to do says nothing about what they do together.

What the studies found

Acute ischemic stroke, Phase I/II (Hernández-Bernal et al., 2024)

• What was given — 36 patients aged 18 to 80, within 12 hours of a CT-confirmed ischemic stroke, randomized and open-label: 75 µg EGF with 3.5 mg GHRP-6 (10 patients) or with 5 mg (10), into a vein twice a day for 7 days, or standard care (16).
• What it found — Serious adverse events: 9 of 16 on standard care, against 3 of 10 and 2 of 10 on the two doses; two events in one patient were attributed to the treatment. The authors report better neurological and functional scores at 90 and 180 days, and more survivors at 6 months, with the combination.
• Limits — 36 patients, open-label, with safety as the main endpoint; run by CIGB, the EGF's maker.

Acute ischemic stroke, Phase III (COURAGE-2) (Hernández-Bernal et al., 2026)

• What was given — 188 patients within 12 hours of an ischemic stroke, randomized and open-label: 75 µg EGF with 5 mg GHRP-6 into a vein twice a day for 7 days (95 patients) or standard care (93).
• What it found — It missed its main goal: disability, daily function and survival did not differ across all patients. In a subgroup of 27 with severe strokes, disability at 6 months was lower and fewer died on the combination, which the authors say calls for further study. Severe adverse events: 30 of 95 treated and 18 of 93 on standard care, not a significant difference; none was judged treatment-related.
• Limits — Open-label; the severe-stroke result is from a subgroup of 27.

Both trials come from CIGB, which makes the EGF, and neither was blinded.